January 2024
Drs. Aguilera and Elghonaimy named part of TMCi's 2024 Accelerator for Cancer Therapeutics cohort
Texas Medical Center Innovation (TMCi) has named Drs. Todd Aguilera and Eslam Elghonaimy as part of their 2024 Accelerator for Cancer Therapeutics cohort, which recognizes health tech innovators working on promising cancer therapeutics.
TMCi news releaseAugust 2023
Dr. Aguilera received White House-sponsored Cancer Moonshot award
Dr. Aguilera has been named one of 11 inaugural Cancer Moonshot Scholars. The national program recognizes a cohort of early-career investigators from underrepresented groups who have been identified as emerging leaders in cancer research and innovation.
White House Press ReleaseJune 2020
Dr. Aguilera received Damon Runyon Award to study emerging immunotherapy
The Damon Runyon Cancer Research Foundation named Dr. Aguilera as one of four new Damon Runyon Clinical Investigators. The three-year, $600,000 award supports outstanding early career physician-scientists conducting patient-oriented cancer research with the potential to impact cancer diagnosis, prevention, and treatment.
Center TimesJuly 2021
Dr. Aguilera awarded SCCC Translational Pilot Award
Dr. Todd Aguilera, member of the Experimental Therapeutics Research Program, along with a multi-PI team, Andrew Jamieson, Ph.D., Assistant Professor of Bioinformatics; Ravikanth Maddipati, M.D., Assistant Professor of Internal Medicine, and Megan Wachsmann, M.D., Assistant Professor of Pathology, were awarded a SCCC Translational Pilot Award for “Interrogation of the Therapeutic Response in Pancreatic Adenocarcinoma to Identify Opportunities to Target the Tumor Immune Microenvironment.”
April 2018
Dr. Aguilera received Distinguished Researcher Award from UTSW President's Research Council
Distinguished Researcher AwardAugust 2017